Cargando…

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters

Glioblastomas (GBM) are heterogeneous highly vascular brain tumors exploiting the unique microenvironment in the brain to resist treatment and anti-tumor responses. Anti-angiogenic agents, immunotherapy, and targeted therapy have been studied extensively in GBM patients over a number of decades with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holst, Camilla Bjørnbak, Pedersen, Henriette, Obara, Elisabeth Anne Adanma, Vitting-Seerup, Kristoffer, Jensen, Kamilla Ellermann, Skjøth-Rasmussen, Jane, Lund, Eva Løbner, Poulsen, Hans Skovgaard, Johansen, Julia Sidenius, Hamerlik, Petra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078714/ https://www.ncbi.nlm.nih.gov/pubmed/33779510 http://dx.doi.org/10.1080/15384101.2021.1901037

Ejemplares similares

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM2B
por: Staberg, Mikkel, et al.
Publicado: (2018)

The HOPX and BLBP landscape and gliogenic regions in developing human brain
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2023)

Replication Protein A (RPA) Mediates Radio-Resistance of Glioblastoma Cancer Stem-Like Cells
por: Pedersen, Henriette, et al.
Publicado: (2020)

SPT6-driven error-free DNA repair safeguards genomic stability of glioblastoma cancer stem-like cells
por: Obara, Elisabeth Anne Adanma, et al.
Publicado: (2020)

Most protein domains exist as variants with distinct functions across cells, tissues and diseases
por: Vitting-Seerup, Kristoffer
Publicado: (2023)

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
por: Urup, Thomas, et al.
Publicado: (2017)

Editorial: Alternative Splicing in Health and Disease
por: Kahraman, Abdullah, et al.
Publicado: (2022)

Changes in Plasma IL-6, Plasma VEGF and Serum YKL-40 During Treatment with Etanercept and Methotrexate or Etanercept Alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
por: Knudsen, Lene Surland, et al.
Publicado: (2009)

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)

Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy
por: Bogetofte Barnkob, Mike, et al.
Publicado: (2022)

Expression and splicing mediate distinct biological signals
por: Dam, Søren Helweg, et al.
Publicado: (2023)

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)

spliceR: an R package for classification of alternative splicing and prediction of coding potential from RNA-seq data
por: Vitting-Seerup, Kristoffer, et al.
Publicado: (2014)

Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection
por: Hedetoft, Morten, et al.
Publicado: (2021)

CAGEfightR: analysis of 5′-end data using R/Bioconductor
por: Thodberg, Malte, et al.
Publicado: (2019)

satuRn: Scalable analysis of differential transcript usage for bulk and single-cell RNA-sequencing applications
por: Gilis, Jeroen, et al.
Publicado: (2022)

VEGF-C as a putative therapeutic target in cancer
por: Michaelsen, Signe R., et al.
Publicado: (2019)

Serum YKL-40 Levels and White Matter Hyperintensities in Patients with Acute Ischemic Stroke
por: Shi, Guomei, et al.
Publicado: (2023)

Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study
por: Schou Nørøxe, Dorte, et al.
Publicado: (2021)

UPF2-Dependent Nonsense-Mediated mRNA Decay Pathway Is Essential for Spermatogenesis by Selectively Eliminating Longer 3'UTR Transcripts
por: Bao, Jianqiang, et al.
Publicado: (2016)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

YKL-40 is a Protective Biomarker for Fatty Liver in World Trade Center Particulate Matter-Exposed Firefighters
por: Cho, Soo Jung, et al.
Publicado: (2014)

Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study
por: Nørøxe, Dorte Schou, et al.
Publicado: (2019)

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
por: Boisen, Mogens K., et al.
Publicado: (2017)

YKL-40 and genetic status of CHI3L1 in a large group of asthmatics
por: Hansen, Jakob W., et al.
Publicado: (2015)

Amplification of pico-scale DNA mediated by bacterial carrier DNA for small-cell-number transcription factor ChIP-seq
por: Jakobsen, Janus S, et al.
Publicado: (2015)

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2023)

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2021)

Circulating VEGF As a Biological Marker in Patients with Rheumatoid Arthritis? Preanalytical and Biological Variability in Healthy Persons and in Patients
por: Hetland, Merete Lund, et al.
Publicado: (2008)

Progression of the pluripotent epiblast depends upon the NMD factor UPF2
por: Chousal, Jennifer N., et al.
Publicado: (2022)

Computational matter
por: Stepney, Susan, et al.
Publicado: (2018)

A Functional Link between Nuclear RNA Decay and Transcriptional Control Mediated by the Polycomb Repressive Complex 2
por: Garland, William, et al.
Publicado: (2019)

Regional and age differences in specialised palliative care for patients with pancreatic cancer
por: Adsersen, Mathilde, et al.
Publicado: (2021)

Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease
por: Schroder, Jakob, et al.
Publicado: (2020)

Development of a New Enzyme-Linked Immunosorbent Assay (ELISA) for Measuring the Content of PACAP in Mammalian Tissue and Plasma
por: Obara, Elisabeth Anne Adanma, et al.
Publicado: (2023)

Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population
por: Allin, K H, et al.
Publicado: (2012)

YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
por: Schultz, Nicolai A., et al.
Publicado: (2010)

The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
por: Dam Mygind, Naja, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pisajifvic10rf6bgvq8vrsggv